Cargando…
Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review
Hepatocellular carcinoma (HCC) and liver cirrhosis are fatal diseases. This study aimed to investigate survival time and palliative care in terminal HCC and/or liver cirrhosis compared with lung cancer. Between January 2004 and December 2010, we enrolled 116 patients with terminal cirrhosis and/or H...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
the Society for Free Radical Research Japan
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652303/ https://www.ncbi.nlm.nih.gov/pubmed/23704814 http://dx.doi.org/10.3164/jcbn.13-8 |
_version_ | 1782269307631173632 |
---|---|
author | Nakashita, Shunya Eguchi, Yuichiro Mizuta, Toshihiko Kuroki, Shigetaka Ono, Naofumi Eguchi, Takahisa Anzai, Keizo Fujimoto, Kazuma |
author_facet | Nakashita, Shunya Eguchi, Yuichiro Mizuta, Toshihiko Kuroki, Shigetaka Ono, Naofumi Eguchi, Takahisa Anzai, Keizo Fujimoto, Kazuma |
author_sort | Nakashita, Shunya |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) and liver cirrhosis are fatal diseases. This study aimed to investigate survival time and palliative care in terminal HCC and/or liver cirrhosis compared with lung cancer. Between January 2004 and December 2010, we enrolled 116 patients with terminal cirrhosis and/or HCC or lung cancer admitted to a municipal hospital in Japan; 48 had liver cirrhosis, 35 HCC and 33 lung cancer. By retrospective chart review, we evaluated: (i) rate of usage of narcotic analgesics and (ii) survival time from onset of coma (Glasgow Coma Scale less than 8). Time between coma and death was significantly shorter in the liver disease patients (cirrhosis and/or HCC: 7.0 h) than in lung cancer (44.0 h, p = 0.045). Total bilirubin was higher in HCC compared with cirrhosis (p<0.01). Rate of usage of narcotic analgesics was higher in lung cancer (20/33: 60.6%) than in liver disease (17/83: 20.5%, p<0.01); analgesics were used more frequently in HCC than in liver cirrhosis (p<0.01). These results suggest that liver cirrhosis and HCC patients do not always require palliative care and that survival time from onset of coma due to liver disease was not prolonged compared with lung cancer. |
format | Online Article Text |
id | pubmed-3652303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | the Society for Free Radical Research Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-36523032013-05-23 Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review Nakashita, Shunya Eguchi, Yuichiro Mizuta, Toshihiko Kuroki, Shigetaka Ono, Naofumi Eguchi, Takahisa Anzai, Keizo Fujimoto, Kazuma J Clin Biochem Nutr Original Article Hepatocellular carcinoma (HCC) and liver cirrhosis are fatal diseases. This study aimed to investigate survival time and palliative care in terminal HCC and/or liver cirrhosis compared with lung cancer. Between January 2004 and December 2010, we enrolled 116 patients with terminal cirrhosis and/or HCC or lung cancer admitted to a municipal hospital in Japan; 48 had liver cirrhosis, 35 HCC and 33 lung cancer. By retrospective chart review, we evaluated: (i) rate of usage of narcotic analgesics and (ii) survival time from onset of coma (Glasgow Coma Scale less than 8). Time between coma and death was significantly shorter in the liver disease patients (cirrhosis and/or HCC: 7.0 h) than in lung cancer (44.0 h, p = 0.045). Total bilirubin was higher in HCC compared with cirrhosis (p<0.01). Rate of usage of narcotic analgesics was higher in lung cancer (20/33: 60.6%) than in liver disease (17/83: 20.5%, p<0.01); analgesics were used more frequently in HCC than in liver cirrhosis (p<0.01). These results suggest that liver cirrhosis and HCC patients do not always require palliative care and that survival time from onset of coma due to liver disease was not prolonged compared with lung cancer. the Society for Free Radical Research Japan 2013-05 2013-05-01 /pmc/articles/PMC3652303/ /pubmed/23704814 http://dx.doi.org/10.3164/jcbn.13-8 Text en Copyright © 2013 JCBN This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Nakashita, Shunya Eguchi, Yuichiro Mizuta, Toshihiko Kuroki, Shigetaka Ono, Naofumi Eguchi, Takahisa Anzai, Keizo Fujimoto, Kazuma Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review |
title | Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review |
title_full | Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review |
title_fullStr | Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review |
title_full_unstemmed | Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review |
title_short | Evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review |
title_sort | evaluation narcotic analgesic use and survival time in terminal stage liver diseases compared with lung cancer: a retrospective chart review |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652303/ https://www.ncbi.nlm.nih.gov/pubmed/23704814 http://dx.doi.org/10.3164/jcbn.13-8 |
work_keys_str_mv | AT nakashitashunya evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview AT eguchiyuichiro evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview AT mizutatoshihiko evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview AT kurokishigetaka evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview AT ononaofumi evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview AT eguchitakahisa evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview AT anzaikeizo evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview AT fujimotokazuma evaluationnarcoticanalgesicuseandsurvivaltimeinterminalstageliverdiseasescomparedwithlungcanceraretrospectivechartreview |